EUVIMEDEUVIMED entdecken
Systematische Übersicht

Mpox Clinical Outcomes in People With and Without HIV Treated With Tecovirimat: A Systematic Review

Santenna Chenchula iD, Krishna Chaitanya Amerneni, Padmavathi Rajakarunakaran, Anitha Kuttiappan, Sunil Kumar Gupta, Satya Prakash, Sri Varshini Talagampala, Mohan Krishna Ghanta iD, Madhavrao Chavan

Reviews in Medical Virology · 2026-05 · 36 (3)

DOI: 10.1002/rmv.70152 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Reviews in Medical Virology, online erschienen am 17.04.2026. Verfasst von Santenna Chenchula und 8 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, Bhopal, India. Hauptthemen laut MEDLINE: Antiviral Agents, Herpesviridae Infections, HIV Infections, Mpox, Monkeypox. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mpox poses heightened risks for immunocompromised individuals, particularly people with HIV (PWH), yet evidence on clinical outcomes and antiviral treatment remains limited. We conducted a systematic review in accordance with PRISMA guidelines, searching MEDLINE, Scopus, and the Cochrane Library from inception through October 2025. Fourteen studies comprising 8867 patients were included. A recently published randomized controlled trial evaluating tecovirimat for mpox was also considered to contextualise the findings. Owing to substantial clinical and methodological heterogeneity, data were synthesised narratively using the Synthesis Without Meta‐analysis (SWiM) framework. Across studies, mpox severity followed a clear CD4‐dependent gradient. People without HIV (PWoH) and PWH with relatively preserved immune function (generally CD4 ≥ 200 cells/μL) typically experienced milder, self‐limiting disease, with treatment failure rates below 5%. In contrast, PWH with CD4 counts < 200 cells/μL, particularly those < 100 cells/μL, demonstrated substantially higher rates of necrotic lesions, proctitis, hospitalisation, delayed viral clearance, and mortality. Treatment failure in this subgroup ranged from 15% to 30%, and all confirmed cases of tecovirimat resistance (3 of 18 tested) occurred in patients with CD4 counts < 100 cells/μL. Observational studies suggested that earlier initiation of tecovirimat (≤ 7 days from symptom onset) was associated with more favourable clinical trajectories. However, randomised controlled trial evidence has not demonstrated a clear efficacy signal, and prolonged treatment courses (21–28 days) were frequently required in patients with advanced HIV, reflecting persistent disease rather than established antiviral benefit. Tecovirimat was generally well tolerated, with mild adverse events reported in approximately 20%–25% of patients and no serious adverse events definitively attributed to therapy across the included studies. Overall, immunological status rather than HIV serostatus alone appeared to be the principal determinant of mpox severity and clinical outcomes, underscoring the importance of CD4‐guided management strategies and targeted resistance surveillance in immunocompromised populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHerpesviridae InfectionsHIV InfectionsMpox, MonkeypoxHumansCD4 Lymphocyte CountRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

HIVmpoxmpox viruspeople with HIVpeople without HIVtecovirimat

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • All India Institute of Medical Sciences, Bhopal, India.
  • University of Arizona, Tucson, Arizona, USA.
  • Mediciti Institute of Medical Sciences, Medchal, Hyderabad, India.
  • School of Pharmacy and Technology Management, SVKM'S NMIMS, Shirpur, India.
  • LN Medical College, Bhopal, India.
  • All India Institute of Medical Sciences, Raipur, India.

ORCID-Profile: Santenna Chenchula, Mohan Krishna Ghanta

Zitieren

APA

Chenchula, S., Amerneni, K. C., Rajakarunakaran, P., Kuttiappan, A., Gupta, S. K., Prakash, S., Talagampala, S. V., Ghanta, M. K., & Chavan, M. (2026). Mpox Clinical Outcomes in People With and Without HIV Treated With Tecovirimat: A Systematic Review. Reviews in Medical Virology, 36(3). https://doi.org/10.1002/rmv.70152

Vancouver

Chenchula S, Amerneni KC, Rajakarunakaran P, Kuttiappan A, Gupta SK, Prakash S, et al. Mpox Clinical Outcomes in People With and Without HIV Treated With Tecovirimat: A Systematic Review. Reviews in Medical Virology. 2026;36(3). doi:10.1002/rmv.70152

BibTeX
@article{Chenchula2026,
  author = {Chenchula, Santenna and Amerneni, Krishna Chaitanya and Rajakarunakaran, Padmavathi and Kuttiappan, Anitha and Gupta, Sunil Kumar and Prakash, Satya and Talagampala, Sri Varshini and Ghanta, Mohan Krishna and Chavan, Madhavrao},
  title = {Mpox Clinical Outcomes in People With and Without HIV Treated With Tecovirimat: A Systematic Review},
  journal = {Reviews in Medical Virology},
  year = {2026},
  volume = {36},
  number = {3},
  doi = {10.1002/rmv.70152}
}
Kostenlos starten →